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Abstract
In multiple myeloma, a long non-coding RNA, KIAA0495 (alias PDAM/TP73-AS1), had been found progressively
downregulated from normal plasma cell to benign monoclonal gammopathy of undetermined significance to
symptomatic myeloma. Herein, by methylation-specific PCR, the putative KIAA0495 promoter was found
unmethylated in all healthy controls (N = 14) but methylated in 50 % of myeloma cell lines (N = 10). KIAA0495
methylation was shown inversely correlated with KIAA0495 expression. However, KIAA0495 methylation was
detected in none of both primary myeloma samples at diagnosis (N = 61) and at relapse/progression (N = 16).
Collectively, despite frequently methylated in cell lines, KIAA0495 methylation appeared unimportant in the
pathogenesis or progression of myeloma.
Keywords: Long non-coding RNA, KIAA0495, DNA methylation, Myeloma, Tumour suppressor
Introduction
Long non-coding RNA (lncRNA) is a novel class of func-
tional RNA molecules >200 nucleotides with little or no
protein-coding capacity [1, 2]. Based on their genomic lo-
cations relative to annotated protein-coding genes,
lncRNAs are broadly classified into intergenic, intragenic,
antisense, pseudogene, or divergent transcripts [3, 4].
Functionally, lncRNAs play a role in, but not limited to,
development, differentiation, and carcinogenesis [2, 5].
Moreover, lncRNAs are found dysregulated and therefore
potentially to be oncogenic or tumour suppressive in hu-
man cancers [6, 7].
Multiple myeloma is a form of haematological cancer
originated from malignant transformation of plasma cells
[8]. Clinically, this disease begins with benign monoclonal
gammopathy of undetermined significance (MGUS), some
of which may undergo asymptomatic smouldering mul-
tiple myeloma (SMM), and progresses to symptomatic
myeloma [9]. Genetically, despite D-type cyclins are
apparently upregulated in all patients, myeloma is a het-
erogeneous disease characterized by specific gains or
losses of chromosomes, or reciprocal translocations, such
as t(4;14)(p16.3;q32) and t(14;16)(q32;q23) [10].
DNA methylation refers to the catalytic addition of a
methyl (−CH3) group to the cytosine ring of a CpG di-
nucleotide [11]. Human cancers are characterized by loss
of global DNA methylation but gain of methylation at
promoter-associated CpG islands (a cluster of CpG di-
nucleotides) and hence transcriptional silencing of spe-
cific tumour suppressor genes or miRNAs [12]. In
myeloma, DNA methylation has been shown to mediate
silencing of multiple tumour suppressor genes and
miRNAs, and has been implicated in the pathogenesis
and prognosis of the disease [13, 14].
Interestingly, by gene expression profiling, KIAA0495, a
lncRNA transcribed from chromosome 1p36, has been
shown to be progressively downregulated from normal
plasma cell to MGUS to symptomatic myeloma [15].
Moreover, methylation-mediated silencing of KIAA0495
has been demonstrated in oligodendroglial tumours, lead-
ing to enhanced cisplatin resistance via upregulation of
anti-apoptotic B-cell CLL/lymphoma 2-like 1 (BCL2L1)
[16]. Hence, we hypothesized that DNA methylation may
account for the progressive downregulation of KIAA0495
in the pathogenesis of myeloma. Herein, we have studied
and reported methylation of KIAA0495 in myeloma cell
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Table 1 Primer sequences and PCR reaction conditions
Primer set Forward primer (5’ – 3’) Reverse primer (5’ – 3’) Product size (bp) MgCl2/Tm/cycles Reference
(I) Methylation-specific polymerase chain reaction (MSP)
KIAA0495
M-MSP TGG AGA TAA CGG GTT TAG AGA AAT C AAC GAA AAC AAA AAT AAA ACC TTC G 191 1.5 mM/58 °C/40X –
U-MSP TGG AGA TAA TGG GTT TAG AGA AAT T AAA CAA AAA CAA AAA TAA AAC CTT CA 192 2.0 mM/58 °C/40X –
(II) Reverse transcription-polymerase chain reaction (RT-PCR)
KIAA0495 GCT GCT TGC TGT ACG TGG TG CGT GGC TGA CAC AAA CTT GC 178 1.5 mM/60 °C/35X [16]
GAPDH ACC ACA GTC CAT GCC ATC ACT TCC ACC ACC CTG TTG CTG TA 452 1.5 mM/60 °C/24X
Keys: Tm, annealing temperature; M-MSP, MSP for the methylated allele; U-MSP, MSP for the unmethylated allele
Fig. 1 Methylation of KIAA0495 in myeloma. a Sequencing analysis of M-MSP products showed that the cytosine [C] residues of CpG dinucleotides
were methylated and remained unchanged after bisulfite conversion, whereas all the other non CpG C residues were unmethylated and converted to
thymidine [T], indicating complete bisulfite conversion and specificity of MSP. b M-/U-MSP showed KIAA0495 was completely methylated in positive
control with methylated DNA, but completely unmethylated in 14 healthy donor controls, including peripheral buffy coat (N1-N10), marrow buffy coat
(N11-N13), and CD138-sorted marrow plasma cells (N14). c M-/U-MSP showed KIAA0495 was partially methylated in KMS-12-PE, LP-1, NCI-H929,
OCI-MY5, and OPM-2, whereas it was completely unmethylated in MOLP-8, RPMI-8226, U-266, WL-2, and JJN-3. d Quantitative bisulfite pyrosequencing
interrogating the methylation intensity on a stretch of 7 neighboring CpG dinucleotides indicated consistent resutls as shown by the MSP statuses
(MM, MU, and UU)
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lines, primary myeloma marrow samples at diagnosis, and
at relapse/progression. Materials and methods have been
incorporated as Additional file 1.
Findings
Methylation-specific PCR: KIAA0495 methylation in
healthy controls and myeloma cell lines
While the putative KIAA0495 promoter region was
found embedded in a CpG island (Additional file 2:
Figure S1), MSP primers were designed to study
methylation of this CpG island in a panel of healthy
controls [peripheral (N = 10) and marrow (N = 3) buffy
coat, CD138-sorted healthy plasma cell (N = 1)], and
myeloma cell lines (N = 10) (Table 1). Direct sequen-
cing analysis of M-MSP products from bisulfite-
treated positive control showed expected conversion
of unmethylated cytosine into uracil (turned to thymi-
dine after PCR), with methylated cytosine remained
unchanged, indicating complete bisulfite conversion
and MSP specificity (Fig. 1a). None of 14 healthy controls
showed KIAA0495 methylation (Fig. 1b). On the other
hand, in myeloma cell lines, KMS-12-PE, LP-1, NCI-H929,
Fig. 2 Methylation and expression of KIAA0495 in myeloma cells. a Semi-quantitative RT-PCR analysis showed expression of KIAA0495 in MOLP-8,
RPMI-8226, U-266, WL-2, and JJN-3, which were completely unmethylated for KIAA0495, but not in KMS-12-PE, LP-1, NCI-H929, OCI-MY5,
and OPM-2, which were partially methylated for KIAA0495 (P = 0.0079). Sequencing analysis confirmed the authenticity of the RT-PCR of
KIAA0495. b qRT-PCR analysis showed the expression of KIAA0495 was significantly higher, as indicated by a lower ΔCt, in methylated than
completely unmethylated myeloma cell lines (P = 0.000155). c Two partially methylated myeloma cell lines, LP-1 and OCI-MY5, were
separately treated with 1 μmol/l of 5-AzadC for 3 days, after which, 5-AzadC was removed and cells were cultured for additional 6 days.
On day 3, upon treatment with 5-AzadC, KIAA0495 was demethylated as indicated by the decreased percentage of methylation intensity
by quantitative bisulfite pyrosequencing, with concommitent KIAA0495 re-expression as measured by qRT-PCR. On day 9, upon removal of
5-AzadC for 6 days, methylation of KIAA0495 was restored with re-suppression of KIAA0495
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OPM-2, and OCI-MY5 were partially methylated,
whereas MOLP-8, RPMI-8226, U-266, WL-2, and JJN-3
were completely unmethylated for KIAA0495 (Fig. 1c).
Moreover, the MSP methylation statuses of controls and
cell lines were confirmed by quantitative bisulfite pyrose-
quencing (Fig. 1d). These data suggested that methylation
of KIAA0495 was tumour-specific, consistent with other
tumour suppressor protein-coding genes and non-coding
miRNAs in myeloma [17–20].
KIAA0495 methylation and expression in myeloma cell
lines
To determine whether KIAA0495 methylation was as-
sociated with silencing of KIAA0495 expression, the
expression level of KIAA0495 was measured by semi-
quantitative RT-PCR and quantitative real-time PCR
(qPCR), and correlated with the KIAA0495 methylation
status as detected by MSP in myeloma cell lines. Of the
10 myeloma cell lines, KIAA0495 methylation was
associated with lower expression as detected by both
semi-quantitative RT-PCR (P = 0.0079; Fig. 2a) and
quantitative real-time PCR (P = 0. 000155; Fig. 2b).
Moreover, myeloma cell lines with KIAA0495 methyla-
tion were treated with a hypomethylating agent, 5-AzadC,
followed by pyrosequencing and qPCR analyses. Upon
5-AzadC treatment, LP-1 and OCI-MY5 cells, which were
partially methylated for KIAA0495, showed progressive
demethylation of the KIAA0495 promoter, as evidenced
by the decreased methylation percentage on a stretch of
seven consecutive CpG dinucleotides, together with con-
comitant re-expression of the KIAA0495 transcript, as il-
lustrated by the increased expression relative to the
untreated control (LP-1: P = 0.0013; OCI-MY5: P = 0.0013;
Fig. 2c). Nevertheless, when 5-AzadC-treated cells were
continually cultured with fresh medium in the absence of
5-AzadC for a further 6 days, methylation of the
KIAA0495 promoter was restored, with simultaneous sup-
pression of the KIAA0495 expression (LP-1: P = 0.0331;
OCI-MY5: P = 0.0447; Fig. 2c). Taken together, the methy-
lation of KIAA0495 was inversely correlated with
KIAA0495 expression level in myeloma cell lines, similar
to the methylation-mediated silencing of KIAA0495 dem-
onstrated in glioma cell lines and primary oligodendroglial
tumour cells [16], suggesting that methylation of the
promoter-associated CpG island emerged to be one of the
mechanisms resulting in the regulation of lncRNAs in
cancer cells.
Methylation-specific PCR: KIAA0495 methylation in
myeloma primary samples at diagnosis and at relapse
To examine if methylation of KIAA0495 was also de-
tected in primary samples, methylation of KIAA0495
was studied in 61 primary samples at diagnosis and 16
primary samples at relapse by MSP. However, none of
these samples showed methylation of KIAA0495
(Fig. 3), indicating methylation of KIAA0495 was
rarely detected in primary myeloma samples. Hence,
similar to the studies of miR-9-1, miR-9-3, and miR-
124-1 [21, 22], these data suggested that methylation
of certain tumour suppressor non-coding miRNAs or
lncRNAs was acquired in vitro during continuous cul-
ture of myeloma cells, hence not pathogenic. There-
fore, methylation was not the mechanism leading to
the progressive downregulation of KIAA0495 from
normal plasma cell to MGUS to symptomatic mye-
loma [15], suggestive of other mechanisms, such as
histone modification and miRNA-mediated repression,
may come into play. For instance, in gastric cancer
cells, histone deacetylation was found to be associated
in the downregulation of a tumour suppressor
lncRNA, FENDRR [23]. Moreover, in breast cancer
cells, miR-21 was shown to target and hence downreg-
ulate the expression of a tumour suppressor lncRNA,
GAS5 [24]. Furthermore, while KIAA0495 resides on
1p36, which has been shown frequently deleted in
newly diagnosed patients with myeloma [25], the loss
of expression of KIAA0495 may be associated with
chromosome deletion. Last but not least, inactivation
of KIAA0495 may also be accounted by haploinsuffi-
ciency, which has been demonstrated in the TP53 in
myeloma [26].
Conclusion
Methylation of KIAA0495 is tumour-specific, leading to
reversible silencing of KIAA0495 expression in myeloma
cell lines. On the other hand, it is rarely detected in pri-
mary samples of myeloma at diagnosis or at relapse, and
hence not responsible for the progressive downregula-
tion of KIAA0495 from normal plasma cell to MGUS to
symptomatic myeloma, as shown by the gene expression
profiling, and remains as a possible in vitro event ac-
quired during continuous culture of myeloma cells.
Fig. 3 Methylation of KIAA0495 in primary myeloma marrow samples
at diagnosis (Dx) and at relapse/progression (R)
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Additional files
Additional file 1: Materials and methods. (DOCX 20 kb)
Additional file 2: Figure S1. Schematic diagram showing the
transcription start sites (TSS) of KIAA0495, distribution of CpG
dinucleotides (red lines), and amplicons of methylation-specific PCR
(green box) and pyrosequencing (purple box). (TIFF 339 kb)
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